2005 Saab 9-3 Linear Turbo 2l I4 Convertible Premium Loaded Fast Fun 60+photos on 2040-cars

Auto blog

Saab still alive and well at New Jersey dealership

We all know the Saab story: a niche automaker that just couldn't last in the quickening pace of an increasingly competitive industry, despite its loyal following. But just because the automaker has all but completely disappeared, it doesn't mean that the loyal following has as well. In fact Saab Automobiles Parts North America estimates there are some 450,000 Saabs still in use in the United States, and many of them are still die-hard brand faithful who are adamantly clinging to the bankrupt brand they love. And many of those loyal customers are still finding a home at Park Avenue Saab in Maywood, NJ. Although the Park Avenue Auto Group operates Acura, BMW and Lotus franchises, it hasn't given up on Saab just because the company isn't making any new cars anymore. Instead it's set up shop in an old Suzuki showroom and is building a growing list of Saab customers across New York, New Jersey and Pennsylvania – parts of that list acquired from other, closed Saab dealers in the region. The dealership stocks spare parts and is ready to perform whatever service and maintenance existing Saab owners might need, but it's also still buying and selling Saabs: used models with low mileage and manufactured as close as possible to the end of production in 2011. So when an owner of an old Saab is ready to trade up, the dealership has something to offer. And many of those loyal customers, according to Automotive News, are willing to pay top dollar rather than switch to another brand. If and when a Saab owner needs to buy something newer – as most will have to – the dealer is ready to introduce them to a new Acura or BMW, but to date, very few have. That's why Park Avenue Saab still sells about 40 used Saabs every month to customers in the vicinity, across the country or even overseas. Between the sales and service departments, the dealership is still turning a brisk business, but unless NEVS, Mahindra or some other knight in shining armor swoops in and manages to do what GM and Spyker couldn't, the dealership's management know the business can't last forever.

Petrolicious keeps our love of the Saab Sonett aflame

German auto designs lean toward function and purpose. Italian designers deliver passion and beauty. The Brits, majesty. American cars, brashness and authority. If you want a funky design, though, you go to Sweden. The land of cheap, do-it-yourself furniture and delicious meatballs knows a thing or six about style and design, and while that character is only now reemerging thanks to a certain string of Volvo concepts, it use to be that Saab was the authority on penning some of the industry's more unique designs.
Take the beautiful Sonett for example - a small coupe whose appearance is a funky mishmash of a Porsche 911 and a Bugeyed Sprite with just a hint of a Citroën DS (it's that convex rear window). It's a positively striking car, made more unique by its two-stroke, three-cylinder powertrain and four-on-the-tree manual transmission. With just 70 horsepower hauling about 1,500 pounds of Swedish style, the Sonett strikes us as an ideal alternative to some of the English sports cars of its day, particularly for those that are looking for something beyond your average MG or Triumph.
For Glenn Roberts, the Sonett was a part of his childhood. His family owned example was originally a special-order item by his parents in 1967. He bought the car from them 13 years later and has never looked back, completing a restoration in 2004. With a story like that, it's not surprising that Roberts and his silver Sonett are the most recent pairing to get some attention from Petrolicious.

NEVS, the company that took over Saab, gets new majority owner

Chinese real estate conglomerate Evergrande Group, a key investor behind troubled electric vehicle startup Faraday Future, has acquired a 51 percent stake in NEVS. That's the Chinese-backed Swedish electric vehicle company that purchased the assets of Saab out of bankruptcy in 2012. The investment by subsidiary Evergrande Health Industry Group was valued at the equivalent of $930 million and is expected to help NEVS develop new EVs. Evergrande said it paid the first installment of $430 million on Jan. 15, with the remainder due by the end of the month. The remaining 49 percent stake is controlled by a holding company controlled by NEVS founder Kai Johan Jiang. "It means that NEVS will get a financial (sic) strong main owner who is very interested in developing our vision about green mobility transport solutions for the future," NEVS CEO Stefan Tilk said in a statement. NEVS, short for National Electric Vehicle Sweden, owns production facilities in Trollhattan, Sweden, and Tianjin, China, with another under construction in Shanghai. In late 2017 the company launched what apparently was limited production of the 9-3 EV, an electric vehicle based — you guessed it — on the old Saab 9-3 platform. The company now says it will be built in Tianjin starting later this year, with components coming from Trollhattan. It boasts a 186-mile range, in-car WiFi and a cabin air filter for the notoriously smoggy Chinese air. It also showed a battery-electric 9-3X concept at CES Asia in 2017, which is likely to be its next model pegged for production. The South China Morning Post, citing local media reports, says two of NEVS' models meet the standards for mass production in China. This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings. Definitely the best promotional video we've ever seen. Evergrande Health first came to Faraday Future's rescue back in 2017 with a promised $2 billion investment, but the two sides later went into arbitration in Hong Kong over a dispute about money following the first infusion of $800 million, leading the automaker to cut staff and wages last year, casting the future of FF into doubt. At the end of 2018, Faraday announced it had entered into a new restructuring agreement with an Evergrande Health subsidiary that sees them end litigation and jettison the previous investment agreement, taking Evergrande's investment in the company to 32 percent.